UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
December 12, 2006
Date of Report (Date of earliest event reported)
Avantogen Oncology, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Nevada | | 33-55254-28 | | 87-0438641 |
(State or Other Jurisdiction
of Incorporation) | | (Commission File Number) | | (IRS Employer
Identification Number) |
2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067
(Address of Principal Executive Offices) (Zip Code)
310-277-2077
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 1 - Registrant’s Business and Operations
| Item 1.01. | Entry into a Material Definitive Agreement. |
On December 12, 2006, registrant entered into an Amendment to Loan Agreement (the “Amendment”) with Chopin Opus One, L.P., a Cayman Islands limited partnership (“Chopin”), pursuant to which Chopin agreed to extend the maturity date of its $1 Million loan to registrant from December 31, 2006 until March 31, 2007. The Amendment is filed as Exhibit 10.1 to this Form 8-K and is incorporated into this Item 1.01 by reference. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of such document.
Section 9 - Financial Statements and Exhibits
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibit is filed with this report:
| | |
| 10.1 | | Amendment to Loan Agreement dated December 12, 2006 between Avantogen Oncology, Inc. and Chopin Opus One, L.P. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| Avantogen Oncology, Inc. |
| |
| By: | | /s/ Christopher Nowers |
| | Christopher Nowers |
| | Chief Executive Officer |
Date: December 18, 2006
EXHIBIT INDEX
| | |
| 10.1 | | Amendment to Loan Agreement dated December 12, 2006 between Avantogen Oncology, Inc. and Chopin Opus One, L.P. |
